NEWS ABOUT HAE
|
|
test
|
|
6/10/2008
|
CSL Behring Submits NDS to Health Canada Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Pivotal phase II/III study demonstrates C1-INH is effective treatment for acute HAE attacks
|
|
5/13/2008
|
New C1-esterase Inhibitor Highly Effective in Hereditary Angioedema
Note - link is dead now.
Reuters Health covered CSL Behring's recent announcement that C1-esterase inhibitor (C1-INH) concentrate is a safe, effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder.
|
|
4/3/2008
|
C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
C1-esterase inhibitor (C1-INH) concentrate is a safe and effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the American Academy of Allergy, Asthma & Immunology (AAAAI) 64th Annual Meeting. Results from the prospective, double-blind International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 1), the largest HAE study ever conducted, showed patients receiving C1-INH concentrate had a median time to symptom relief of 30 minutes, versus 90 minutes for patients receiving placebo. Additionally, interim results from I.M.P.A.C.T. 2, also presented at AAAAI, demonstrated for the first time C1-INH replacement therapy's effectiveness in rapidly relieving HAE attacks in peripheral body locations, such as the hands and feet.
|
|
3/25/2008
|
CSL Behring Submits Application to FDA for HAE Treatment
CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
|
|
3/6/2008
|
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities.
|
|
11/29/2007
|
Novel Therapies May At Last Bring Relief for U.S. Hereditary Angioedema Patients
Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) ¿ a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening ¿ hope is on the horizon according to a team of experts presenting the latest research at the ACAAI Annual Meeting.
|
|
11/27/2007
|
CSL Behring Completes Enrollment of Phase III Clinical Study of C1 Inhibitor in Treating Hereditary Angioedema
CSL Behring announced today that it has completed patient enrollment of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE).
|
|
10/12/2007
|
Key Issues Dialogue: HAE & Primary Immune Disease
In February, three well-known members of the U.K. primary immunodeficiency community met with Eddie Owens of CSL Behring to discuss challenges and advances in diagnosis and treatment.
|
|
10/8/2007
|
Suwanee mother of two finds relief from rare disease in local study.
Raising twin girls can be a challenging
experience for any parent,
but Joyce Wilmot of Suwanee
lives with the threat of a rare condition
that - at any moment - can
leave her unable to care for her
children for as long as a week.
|
|
4/20/2007
|